ArticleFuture oncology (London, England)2025

A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale.

Andre R Kydd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.